Table 1 Characteristics of included studies
Study, Year(Reference) | Research type | Publication | Area | Agea | Sex (male/female) | Samplesize | Sample type | Proteinuria (g/day)ab | Serum Creatinine (mg/dl)ab | TreatmentWith ISa | Time from biopsy(Mo.) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Hoxha et al. 20118 | Prospective | Full txt | Germany | NA | NA | 117 | Serum | “nonNS-NS” | NA | 55%&29% | NA |
McGettigan et al. 201217 | Retrospective | Abstract | Australia | NA | NA | 32 | Serum | NA | NA | NA | NA |
Qin et al. 20119 | Prospective | Full txt | China | 41 | 61/35c | 106 | Serum | 3.51–13.5&3.51–14.43 | 0.4–3.92&0.22–1.46 | None | 0 |
Oh et al. 201310 | Prospective | Full txt | Korea | 54.7 | 51/49c | 109 | Serum | 3.17–9.86 | 0.91 ± 0.35 | None | 0 |
Kimura et al. 201218 | Retrospective | Abstract | Japan | NA | NA | 36 | Serum | NA | NA | NA | NA |
Ardalan et al. 201311 | Retrospective | Full txt | Iran | 34 | 13/12 | 25 | Serum | 0.7–4.9 | 1.0–9.5 | all | 7–71 |
Hoxha et al. 201212 | Prospective | Full txt | Germany | 56.5&57.7 | 64/24 | 88 | Serum + Tissue | 0.1–33&0.77–22.7 | 0.5–5.28&0.7–2.7 | None | 0–11 |
Bajcsi et al. 201319 | Retrospective | Abstract | Hungary | NA | NA | 6 | Serum | NA | NA | NA | 0 |
Svobodova et al. 201313 | Retrospective | Full txt | Czech | 52.6 | NA | 84 | Serum + Tissue | 10.1 ± 7.6 | 1.22 ± 0.58 | None | 0 |
Svobodova et al. 201220 | Retrospective | Abstract | Czech | NA | NA | 28 | Serum | 8.6 ± 3.6&9.3 ± 8.3 | NA | None | 0 |
Schonermarck et al. 201221 | Retrospective | Abstract | Germany | NA | NA | 34 | Serum | NA | NA | NA | NA |
Beck et al. 20097 | Retrospective | Full txt | USA | 47&38 | 28/17 | 45 | Serum | 0.6–14&0.3–9.1 | 0.4–3.1&0.5–0.8 | 34%&43% | 0–132 |
Kanigicherla et al. 201314 | Retrospective | Full txt | UK | 54 | 64/26c | 109 | Serum | 5.9–12.8 | 0.86–1.37 | 30% | NA |
Larsen et al. 201216 | Retrospective | Full txt | USA | 57.5&47.4 | 89/76 | 165 | Tissue | 7.3 ± 5&5.7 ± 4.7 | 1.4 ± 0.9 &1.7 ± 1.7 | NA | 0 |
Barrett et al. 201415 | Retrospective | Full txt | USA | 69 | 3/4 | 7 | Tissue | 1–11&1.5–9 | 1.2–4.1&1.1–5.7 | all | 0 |
Medrano et al. 201422 | Retrospective | Full txt | Spain | 52.3 | 41/23 | 64 | Serum + Tissue | 8.6–15&7.55–11 | 1.1 ± 0.55&1 ± 0.27 | NA | NA |
Meneses et al. 201423 | Retrospective | Abstract | Portugal | NA | NA | 38 | Serum | NA | NA | NA | NA |
Brenchley et al. 201424 | Retrospective | Abstract | UK | NA | NA | 26 | Serum | NA | NA | NA | NA |
Gasim et al. 201425 | Retrospective | Abstract | USA | 54 | 21/20 | 41 | Tissue | NA | NA | NA | NA |
